UNICA IRIS Institutional Research Information System

DEMELIA, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 105.770
NA - Nord America 5.268
AS - Asia 2.015
SA - Sud America 294
AF - Africa 33
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 113.385
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 104.142
US - Stati Uniti d'America 5.220
CN - Cina 989
SG - Singapore 732
UA - Ucraina 544
DE - Germania 321
SE - Svezia 299
BR - Brasile 238
FI - Finlandia 162
GB - Regno Unito 157
VN - Vietnam 93
FR - Francia 53
KR - Corea 49
RU - Federazione Russa 31
CA - Canada 24
AR - Argentina 22
IN - India 22
BD - Bangladesh 18
HK - Hong Kong 18
ID - Indonesia 16
JP - Giappone 14
BE - Belgio 13
EC - Ecuador 13
MX - Messico 13
IQ - Iraq 9
PK - Pakistan 9
AT - Austria 8
TR - Turchia 8
ZA - Sudafrica 8
MA - Marocco 7
PL - Polonia 7
IL - Israele 6
NL - Olanda 6
ES - Italia 5
KE - Kenya 5
VE - Venezuela 5
CO - Colombia 4
DK - Danimarca 4
PE - Perù 4
SA - Arabia Saudita 4
CH - Svizzera 3
CR - Costa Rica 3
EU - Europa 3
IE - Irlanda 3
IR - Iran 3
MY - Malesia 3
NG - Nigeria 3
TN - Tunisia 3
UZ - Uzbekistan 3
AL - Albania 2
AZ - Azerbaigian 2
CL - Cile 2
CZ - Repubblica Ceca 2
EG - Egitto 2
GE - Georgia 2
HN - Honduras 2
JO - Giordania 2
LB - Libano 2
MU - Mauritius 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PY - Paraguay 2
RO - Romania 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AU - Australia 1
BB - Barbados 1
BO - Bolivia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GY - Guiana 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
NP - Nepal 1
PH - Filippine 1
PT - Portogallo 1
SD - Sudan 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 113.385
Salva come PNG Salva come JPEG
Città #
Cagliari 102.738
Uta 1.136
Fairfield 549
Woodbridge 426
Chandler 385
Singapore 363
Houston 336
Ann Arbor 335
Ashburn 335
Jacksonville 288
Boardman 271
Wilmington 247
Dallas 238
Dearborn 222
Nyköping 220
Cambridge 215
Seattle 194
Beijing 193
Santa Clara 91
Hefei 88
Nanjing 87
Los Angeles 83
New York 71
Helsinki 69
Boston 65
Shanghai 65
Seoul 46
Buffalo 40
Milan 37
Nanchang 36
Guangzhou 32
San Diego 32
Shenyang 32
Munich 30
Ho Chi Minh City 29
Hebei 27
Jiaxing 27
São Paulo 27
The Dalles 27
Verona 26
Changsha 23
London 20
Orange 20
Toronto 19
Hong Kong 17
Auburn Hills 16
Dong Ket 16
Mountain View 16
Redwood City 16
Redondo Beach 15
Jinan 14
Tianjin 14
Tokyo 14
Brussels 13
Norwalk 13
Turku 13
Hanoi 12
Kunming 12
Ningbo 11
Washington 11
Brooklyn 9
Manchester 9
Rome 9
Ansbach 8
Porto Alegre 8
San Francisco 8
Sassari 8
Zhengzhou 8
Brasília 7
Chicago 7
Phoenix 7
Columbus 6
Düsseldorf 6
Guayaquil 6
Rio de Janeiro 6
Taizhou 6
Atlanta 5
Caxias do Sul 5
Frankfurt am Main 5
Jakarta 5
Lahore 5
Nuremberg 5
Perugia 5
Saint Petersburg 5
Wuhan 5
Belo Horizonte 4
Biên Hòa 4
Borås 4
Chengdu 4
Chennai 4
Delhi 4
Denver 4
Dhaka 4
Hangzhou 4
Johannesburg 4
Lauterbourg 4
Mexico City 4
Nairobi 4
Portsmouth 4
Ribeirão Preto 4
Totale 110.286
Salva come PNG Salva come JPEG
Nome #
Proteomic investigation of whole saliva in Wilson's disease 4.286
null 3.544
Bipolar disorders and Wilson's disease 3.196
The burden of depressive and bipolar disorders in celiac disease 2.897
Coeliac disease and psychiatric comorbidity: epidemiology, pathophysiological mechanisms, quality-of-life, and gluten-free diet effects 2.720
Value of histochemical stains for copper in the diagnosis of Wilson's disease 2.695
Late onset Wilson's disease 2.526
Premature vascular deterioration in young patients affected by Wilson's disease: a pilot study 2.505
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.404
Homogeneous magnetic resonance imaging of brain abnormalities in bipolar spectrum disorders comorbid with Wilson's disease 2.385
Mutation analysis of the ATP7B gene in a new group of Wilson's disease patients: Contribution to diagnosis. 2.332
Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease 2.314
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.267
A Top-Down proteomic study of the whole saliva of subjects affected by Wilson disease reveals qualitative and quantitative alterations of the S100A8 and S100A9 proteins 2.220
Psychiatric comorbidity in Wilson’s disease 2.200
Potential biomarker discover of the Wilson’s disease by top-down proteomic investigation of whole saliva 2.065
Quality of life and psychiatric symptoms in wilson's disease: The relevance of bipolar disorders 2.034
Histologic evolution and long-term outcome of Wilson's disease: results of a single-center experience 1.895
The relationship between copper and steatosis in Wilson's disease 1.830
TT virus infection in Italy: prevalence and genotypes in healthy subjects, viral liver diseases and asymptomatic infections by parenterally transmitted viruses 1.820
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.805
Non-invasive assessment of silent liver fibrosis in patients with systemic sclerosis 1.756
Fine structure of hepatic sinusoids in Wilson’s disease. A scanning electron microscopic study 1.753
A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B 1.721
null 1.710
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 1.699
Reversibility of fibrosis in Wilson disease 1.608
Uneven hepatic copper distribution in Wilson's disease 1.579
Kayser-Fleischer ring in Wilson's disease: a cohort study 1.533
Non-invasive assessment of hepatic fibrosis in a series of patients with Wilson's Disease 1.498
Secondary RBD in a patient affected by chronic hepatic encephalopathy: a case report. 1.457
Brain MR spectroscopy in the evaluation of Wilson's disease: Correlation with clinical status and response to therapy 1.456
HBV and HCV infections in Wilson's disease patients: Copper overload could be protective? 1.443
null 1.366
Dynamic 99mTc-HIDA hepatobiliary scintigraphy in vanishing bile duct syndrome 1.291
Animal models are reliably mimicking human diseases? A morphological study that compares animal with human NAFLD 1.255
Peginterferon-alpha-2a plus adefovir vs. peginterferon alpha-2a for 48 weeks in hbeag-negative chronic hepatitis B: Preliminary 24-week results of the peg for B randomized multicenter trial 1.210
Usefulness of dynamic hepatobiliary scintigraphy in Wilson's disease 1.196
Wilson’s disease with late onset 1.182
Patterns of chronic hepatitis B in Central Italy: a cross-sectional study. 1.123
HFE gene mutations and Wilson's disease in Sardinia 985
Tolerability of Peg interferon-alpha 2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency 982
Resolved Psychosis after Liver Transplantation in a Patient with Wilson's Disease 975
Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis 974
Syncitial giant cell hepatitis. A case report 971
[Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy]. FT Effetto a breve termine della terapia con DL-carnitina per os ed L-carnitina e.v. nei pazienti uremici cronici in trattamento emodialitico. 953
Massive haemosiderosis in Wilson’s disease 953
A randomized controlled trial of pegylated interferon-alpha 2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B 942
HFE gene mutations and Wilson's disease in Sardinia 936
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study 936
Massive haemosiderosis in Wilson's disease - Reply 921
Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy 919
SEQUENTIAL PEGINTERFERON ALPHA-2A AND TELBIVUDINE OR VICE VERSA FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B: PRELIMINARY END-OF-TREATMENT RESULTS OF THE TEL-B-PEG RANDOMIZED TRIAL 900
Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease 900
Clinical features of Wilson's disease in Sardinia 835
Massive hepatic haemosiderosis in Wilson's disease 821
Interferon beta-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C 816
A randomized controlled trial of amantadine plus interferon-alpha 2a vs. interferon-alpha 2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha 2a monotherapy 814
Dosage of the hepatic copper in the normal range in a patient affected by Wilson’s disease. 765
Wilson’s disease with late onset 730
Syncitial giant cell hepatitis: a new form of chronic liver disease 695
Peginterferon alpha-2a (40kD) monotherapy vs peginterferon alpha-2a and ribavirin in naive patients with chronic hepatitis C: Preliminary results of the SMIEC II trial in patients with early viral clearance on peginterferon monotherapy 669
Unusual evolution from overt autoimmune hypothyroidism to hyperthyroidism after IFN-α therapy for chronic hepatitis. 651
Ductular reaction and oval cell prolipheration in chronic hepatitis C. 644
Enhanced response to peginterferon-alpha-2a-based triple therapy in previously non-responsive chronic hepatitis C: Final results of pretty study RID E-8970-2010 622
Chronic viral hepatitis in Hiv + drug addicts 612
Epidemiologic study of hepatolenticular degeneration (Wilson's disease) in Sardinia (1902-1983) 598
Comparison of MRI, EEG, EPs and ECD-SPECT in Wilson's disease 593
Computerized cranial tomography in presymptomatic and hepatic form of Wilson's disease 580
Final results of the SMIEC trial in natve patients with hepatitis C: Double therapy (peginterferonalfa2a+ribavirin) vs peginterferon monotherapy in early viral responders and vs triple therapy (peginterferon plus ribavirin plus amantadine) in early non responders 559
[Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis]. FT La precallicreina plasmatica (fattore Fletcher) nella cirrosi epatica. 546
Wilson's disease maps between the D13S169 and D13S173 loci 544
HCV transmission in family members of subjects with HCV related chronic liver disease 520
null 520
alpha 2 Antiplasmin and disseminated intravascular coagulation in liver cirrhosis 516
Predictive testing for Wilson's disease using tightly linked and flanking DNA markers 514
Diagnostic value of 24 hr urinary copper excretion after penicillamine challenge in the adult Wilson's disease patients. 498
Coagulazione, fibrinolisi e shunt porto-sistemico nelle epatopatie croniche 481
HDL-cholesterol in chronic uremia during hemodialytic treatment 467
IS INTRAPULMONARY SHUNT IN CIRRHOTIC-PATIENTS CORRELATED WITH PORTACAVAL-SHUNT 465
Idiopathic adulthood ductopenia presenting with chronic recurrent cholestasis. A case report 444
A randomized controlled trial of amantadine plus interferon alpha-2a vs interferon-alpha-2a in naive patients with chronic hepatitis C randomized based on early response to interferon alpha-2a alone. 442
Pseudo-porphyria cutanea tarda in patients hemodialyzed for chronic renal insufficiency. Clinical, metabolic and immunological aspect 424
Usefulness and limitations of determination of lactate dehydrogenase enzymes in the diagnosis of liver diseases 413
Transient elastography in patients with chronic autoimmune hepatitis: is a goog tool in evaluation of hepatic fibrosis? 376
The role of a double liver needle biopsy in the diagnosis of Wilson's disease. 359
Hypothalamo-pituitary-adrenal function in liver cirrhosis of viral etilogy 354
Diagnostic value of histochemical stains for copper in Wilson's disease 350
ABNORMAL PULMONARY EPITHELIAL PERMEABILITY IN LIVER-CIRRHOSIS 340
Efficacy of lamivudine in patients with antiHBe plus chronic active hepatitis B. 336
Efficacy and safety of long-term IFN therapy in active chronic hepatitis D: Six years of sustained response to the treatment. Case report. 333
Serum ALT level, phlebotomy treatment and alpha-interferon therapy in chronic hepatitis C. 261
Totale 113.530
Salva come PNG Salva come JPEG
Categoria #
all - tutte 144.870
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 144.870
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111.071 0 0 0 0 0 3.298 2.232 1.657 514 1.476 1.124 770
2021/20227.452 652 615 443 495 513 825 601 319 419 514 902 1.154
2022/20238.388 993 1.192 1.086 737 831 914 320 665 385 416 485 364
2023/20247.300 491 421 320 788 762 1.091 953 480 343 536 588 527
2024/20259.186 2.045 2.139 1.148 944 599 643 817 93 211 156 184 207
2025/20262.062 242 280 581 508 302 149 0 0 0 0 0 0
Totale 113.530